亚洲精品成人免费_91女神娇喘疯狂3p之夜_精品韩国一级久久_av毛片网_www超碰com_午夜视频体内射.COM.COM

法國Nanobiotix  
Nanobiotix是一家納米醫(yī)藥公司，總部在法國巴黎，致力于開發(fā)抗癌新藥。公司整合了納米科技與生物技術(shù)的優(yōu)勢。Nanobiotix衍生于布法羅的紐約州立大學(xué)，成立于2003年。其資金來源于幾家領(lǐng)先的歐洲風(fēng)投公司（Matignon Investissement & Gestion、OTC Asset Management、Cap Decisif Management、Amorcage Rhone-Alpes、CM-CIC Capital Innovation和Masseran Gestion）。Nanobiotix已開發(fā)出若干種新化合物，其目標(biāo)是提升自身在納米醫(yī)藥領(lǐng)域的領(lǐng)先地位。

Nanobiotix is a nanomedicine company that intends to revolutionize cancer treatment. Nanobiotix is focused on the development of NanoXray, its innovative pipeline based on a physical mechanism of action with deposit of high quantity of energy within the tumor cells. Nanobiotix is committed to provide patients with meaningful local cancer treatment.

NanoXray products interact with radiotherapy improving the tumor control using the existing standard radiation equipment available in almost every hospital world-wide. Radiation is a standard therapy used in the treatment of approximately 60% of cancer patients.

Nanobiotix is based in Paris, France. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo that was incorporated in 2003 and has been primarily funded by leading European venture capital firms (Matignon Technologies, OTC Asset Management, Cap Decisif, Amorcage Rhone-Alpes, CM-CIC Capital Innovation, Masseran Gestion-CGE). Today, the company has more than 30 employees and has received total funding to date more than € 26 million.

With the development of numerous new compounds, Nanobiotix’s objective is to increase its leading position in nanomedicine field. A major milestone and validation of Nanobiotix approach is its First-in-Human clinical study of NanoXray therapeutics for refractory solid tumors in 2011.